Noting that pharmaceutical interventions for neuropathy can have side effects, researchers are beginning a study on the effects of cannabis to treat neuropathic pain in patients with diabetic peripheral neuropathy.

Lead researcher Stephen Barrett, DPM, FACFAS, believes there is an indication for cannabis when conventional therapies such as gabapentin (Neurontin, Pfizer) or pregabalin (Lyrica, Pfizer) do not provide any substantive relief of the patient’s neuropathic pain.

“There are patients who want something natural but there is a huge stigma for many patients with very severe symptoms who need to be educated about the properties of the medical marijuana, and that ameliorates much of the perception,” says Dr. Barrett, an Adjunct Professor within the Arizona Podiatric Medicine Program at the Midwestern University College of Health Sciences.


Read the full article at:

Author(s): Brian McCurdy

Latest news